STOCK TITAN
  1. Home
  2. SEC Filings
  3. TRDA
  4. [Form 4] Entrada Therapeutics, Inc. Insider Trading Activity

Entrada Therapeutics 10% holder sells 62,714 shares

Filing Impact
(Neutral)
Filing Sentiment

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment worksHow the balance works

Form Type
4

Rhea-AI Filing Summary

Entrada Therapeutics, Inc. (TRDA) reported that investment funds affiliated with MPM BioVentures, as ten percent owners, sold a total of 62,714 shares of Common Stock in open‑market or private transactions on August 24–26, 2026 at weighted‑average prices described in price ranges between approximately $6.97 and $7.64 per share.

The sales were executed indirectly through multiple MPM BioVentures partnerships and LLCs, and each reporting person disclaims beneficial ownership except to the extent of its or his pecuniary interest. After the August 26, 2026 transactions, MPM BioVentures entities collectively continued to hold substantial TRDA positions as detailed in the footnotes.

Insider MPM BioVentures 2014, L.P., EVNIN LUKE, GADICKE ANSBERT, Foley Todd, MPM BioVentures 2014 (B), L.P., MPM Asset Management Investors BV2014 LLC, MPM BioVentures 2014 LLC, MPM BioVentures 2014 GP LLC, MPM BIOVENTURES 2018 (B), L.P., MPM ASSET MANAGEMENT INVESTORS BV2018 LLC
Role 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner
Sold 62,714 shs ($462K)
Type Security Shares Price Value
Sale Common Stock F8, F9, F4, F10 14,569 $7.06 $103K
Sale Common Stock F5, F6, F4, F7 26,522 $7.54 $200K
Sale Common Stock F1, F2, F3, F4 21,623 $7.34 $159K
Holdings After Transaction: Common Stock — 4,318,348 shares (Indirect, See Footnote)
Footnotes (10)
  1. F1. The shares were sold as follows: 9,819 by MPM BioVentures 2014, L.P. ("BV 2014"), 655 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 338 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 10,077 by MPM BioVentures 2018, L.P. ("BV 2018"), 535 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 199 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC.
  2. F2. Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.0852 to $7.58 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  3. F3. The shares are held as follows: 1,979,549 by BV 2014, 132,032 by BV 2014(B), 68,137 by AM BV2014, 2,031,644 by BV 2018, 107,980 by BV 2018(B) and 40,097 by AM BV2018.
  4. F4. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
  5. F5. The shares were sold as follows: 12,043 by BV 2014, 803 by BV 2014(B), 415 by AM BV2014, 12,360 by BV 2018, 657 by BV 2018(B) and 244 by AM BV2018.
  6. F6. Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.28 to $7.6421 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  7. F7. The shares are held as follows: 1,967,506 by BV 2014, 131,229 by BV 2014(B), 67,722 by AM BV2014, 2,019,284 by BV 2018, 107,323 by BV 2018(B) and 39,853 by AM BV2018.
  8. F8. The shares were sold as follows: 6,615 by BV 2014, 441 by BV 2014(B), 228 by AM BV2014, 6,790 by BV 2018, 361 by BV 2018(B) and 134 by AM BV2018.
  9. F9. Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.97 to $7.55 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  10. F10. The shares are held as follows: 1,960,891 by BV 2014, 130,788 by BV 2014(B), 67,494 by AM BV2014, 2,012,494 by BV 2018, 106,962 by BV 2018(B) and 39,719 by AM BV2018.
Total shares sold 62,714 shares Aggregate of three Common Stock sale transactions reported for August 24–26, 2026
Shares sold on August 24, 2026 21,623 shares Common Stock sale coded "S" on 2026-08-24
Shares sold on August 25, 2026 26,522 shares Common Stock sale coded "S" on 2026-08-25
Shares sold on August 26, 2026 14,569 shares Common Stock sale coded "S" on 2026-08-26
Price range on August 24, 2026 $7.0852 to $7.58 per share Footnote states sale price ranged within this band; weighted average price reported
Price range on August 25, 2026 $7.28 to $7.6421 per share Footnote states sale price ranged within this band; weighted average price reported
Price range on August 26, 2026 $6.97 to $7.55 per share Footnote states sale price ranged within this band; weighted average price reported
Post‑August 26, 2026 holdings by BV 2014 1,960,891 shares Common Stock held by BV 2014 as described in the latest holdings footnote
weighted average sale price financial
"Price represents the weighted average sale price of the shares sold."
beneficial ownership regulatory
"Each Reporting Person disclaims beneficial ownership of the securities..."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"except to the extent of his or its respective pecuniary interest therein."
ten percent owner regulatory
"each reporting person is indicated as a ten percent owner of the issuer."
indirect ownership financial
"direct_or_indirect code "I" indicates indirect ownership through entities."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many Entrada Therapeutics (TRDA) shares were sold in this Form 4?
The reporting MPM BioVentures entities sold a total of 62,714 shares of Entrada Therapeutics, Inc. Common Stock in the reported transactions, based on the Form 4 transaction summary covering sales on August 24, 25 and 26, 2026.

On what dates did the MPM BioVentures entities sell TRDA stock?
The sales of Entrada Therapeutics (TRDA) Common Stock by the MPM BioVentures affiliated entities occurred on August 24, 2026, August 25, 2026, and August 26, 2026, as reported in the Form 4 non‑derivative transaction table.

What prices did the MPM BioVentures entities receive for the TRDA share sales?
For the August 24–26, 2026 sales, the Form 4 reports weighted average sale prices, with disclosed price ranges from $6.97 to $7.58 per share on August 24, $7.28 to $7.6421 on August 25, and $6.97 to $7.55 on August 26.

Were the TRDA sales by MPM BioVentures made under a Rule 10b5-1 trading plan?
No. The Form 4’s Rule 10b5‑1 checkbox is not checked, and there is no footnote indicating that the August 24–26, 2026 sales of Entrada Therapeutics (TRDA) shares were executed pursuant to a Rule 10b5‑1 trading plan.

Are the TRDA shares held by MPM BioVentures owned directly or indirectly?
The shares are reported as held indirectly through entities including BV 2014, BV 2014(B), AM BV2014, BV 2018, BV 2018(B) and AM BV2018, and each reporting person disclaims beneficial ownership except to the extent of its or his pecuniary interest.

How many TRDA shares did the MPM BioVentures entities hold after the latest reported sale?
After the August 26, 2026 sales, the footnotes state that the entities held 1,960,891 shares by BV 2014, 130,788 by BV 2014(B), 67,494 by AM BV2014, 2,012,494 by BV 2018, 106,962 by BV 2018(B), and 39,719 by AM BV2018.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Available on EDGAR Accepted by SEC EDGAR
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
MPM BioVentures 2014, L.P.
(Last)(First)(Middle)
C/O MPM BIOIMPACT
399 BOYLSTON STREET, SUITE 1100
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Entrada Therapeutics, Inc. [ TRDA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
DirectorX10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/24/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
XForm filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/24/2026S21,623(1)D$7.34(2)4,359,439ISee Footnote(3)(4)
Common Stock08/25/2026S26,522(5)D$7.54(6)4,332,917ISee Footnote(4)(7)
Common Stock08/26/2026S14,569(8)D$7.06(9)4,318,348ISee Footnote(4)(10)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
1. Name and Address of Reporting Person*
MPM BioVentures 2014, L.P.
(Last)(First)(Middle)
C/O MPM BIOIMPACT
399 BOYLSTON STREET, SUITE 1100
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
EVNIN LUKE
(Last)(First)(Middle)
C/O MPM BIOIMPACT
399 BOYLSTON STREET, SUITE 1100
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
GADICKE ANSBERT
(Last)(First)(Middle)
C/O MPM BIOIMPACT
399 BOYLSTON STREET, SUITE 1100
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Foley Todd
(Last)(First)(Middle)
C/O MPM BIOIMPACT
399 BOYLSTON STREET, SUITE 1100
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
MPM BioVentures 2014 (B), L.P.
(Last)(First)(Middle)
C/O MPM BIOIMPACT
399 BOYLSTON STREET, SUITE 1100
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
MPM Asset Management Investors BV2014 LLC
(Last)(First)(Middle)
C/O MPM BIOIMPACT
399 BOYLSTON STREET, SUITE 1100
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
MPM BioVentures 2014 LLC
(Last)(First)(Middle)
C/O MPM BIOIMPACT
399 BOYLSTON STREET, SUITE 1100
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
MPM BioVentures 2014 GP LLC
(Last)(First)(Middle)
C/O MPM BIOIMPACT
399 BOYLSTON STREET, SUITE 1100
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
MPM BIOVENTURES 2018 (B), L.P.
(Last)(First)(Middle)
C/O MPM BIOIMPACT
399 BOYLSTON STREET, SUITE 1100
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
MPM ASSET MANAGEMENT INVESTORS BV2018 LLC
(Last)(First)(Middle)
C/O MPM BIOIMPACT
399 BOYLSTON STREET, SUITE 1100
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
Explanation of Responses:
1. The shares were sold as follows: 9,819 by MPM BioVentures 2014, L.P. ("BV 2014"), 655 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 338 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 10,077 by MPM BioVentures 2018, L.P. ("BV 2018"), 535 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 199 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC.
2. Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.0852 to $7.58 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
3. The shares are held as follows: 1,979,549 by BV 2014, 132,032 by BV 2014(B), 68,137 by AM BV2014, 2,031,644 by BV 2018, 107,980 by BV 2018(B) and 40,097 by AM BV2018.
4. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
5. The shares were sold as follows: 12,043 by BV 2014, 803 by BV 2014(B), 415 by AM BV2014, 12,360 by BV 2018, 657 by BV 2018(B) and 244 by AM BV2018.
6. Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.28 to $7.6421 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
7. The shares are held as follows: 1,967,506 by BV 2014, 131,229 by BV 2014(B), 67,722 by AM BV2014, 2,019,284 by BV 2018, 107,323 by BV 2018(B) and 39,853 by AM BV2018.
8. The shares were sold as follows: 6,615 by BV 2014, 441 by BV 2014(B), 228 by AM BV2014, 6,790 by BV 2018, 361 by BV 2018(B) and 134 by AM BV2018.
9. Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.97 to $7.55 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
10. The shares are held as follows: 1,960,891 by BV 2014, 130,788 by BV 2014(B), 67,494 by AM BV2014, 2,012,494 by BV 2018, 106,962 by BV 2018(B) and 39,719 by AM BV2018.
Remarks:
See Form 4 for MPM BioVentures 2018, L.P for additional members of this joint filing.
/s/ Luke Evnin08/26/2026
/s/ Ansbert Gadicke08/26/2026
/s/ Todd Foley08/26/2026
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the managing member of MPM BioVentures 2014 GP LLC, the general partner of MPM BioVentures 2014 (B), L.P.08/26/2026
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC08/26/2026
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the managing member of MPM BioVentures 2014 GP LLC08/26/2026
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2018 LLC, the managing member of MPM BioVentures 2018 GP LLC, the general partner of MPM BioVentures 2018 (B), L.P.08/26/2026
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the manager of MPM Asset Management Investors BV2014 LLC08/26/2026
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the managing member of MPM BioVentures 2014 GP LLC, the general partner of MPM BioVentures 2014, L.P.08/26/2026
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2018 LLC, the manager of MPM Asset Management Investors BV2018 LLC08/26/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

Keep reading

More on TRDA

All TRDA news

Trending in the feed

CLIK
Click Holdings Limited (NASDAQ: CLIK) Reports Record Full-Year Results: Revenue, Gross Profit and Net Income Hit New Highs; Every Segment Delivers Record Revenue Open the live feed